ASEAN Heart Journal

First online: 

Case Reports

New Oral Anticoagulants

Chee Yen Lin

05 December 2014

April 2014, 22:2

Case Reports

  • Facebook Social Icon
  • Twitter Social Icon
  • Google+ Social Icon

Reference Tools

References

1. http://eservice.hsa.gov.sg/prism/common/enquirepublic/SearchDRBProduct.do?action=load  (accessed 10 March 2014).

2. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:9S–16S.

CrossRef

 

3. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor–after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005 Dec;61(12):873-80. Epub 2005 Nov 17.

PubMed     CrossRef

 

4. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm  (accessed 10 March 2014).

 

5. Friedman RJ, Dahl OE, Rosencher N, Caprini JA, Kurth AA, Francis CW, Clemens A, Hantel S, Schnee JM, Eriksson BI; RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res. 2010 Sep;126(3):175–82. doi: 10.1016/j. thromres.2010.03.021. Epub 2010 May 15.

PubMed     CrossRef

6. Turpie AG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Kakkar AK. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost. 2011 Mar;105(3):444–53. doi: 10.1160/TH10-09-0601. Epub 2010 Dec 6.

PubMed     CrossRef

7. Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Raskob GE, Berkowitz SD, Wells PS; EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013 Sep 20;11(1):21.

PubMed    CrossRef

 

8. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139–51.

PubMed     CrossRef

 

9. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883–91.

PubMed     CrossRef

10. Ng HJ, Chee YL, Ponnudurai K, Lim LC, Tan D, Tay JC, Handa PK, Akbar Ali M, Lee LH. Consensus recommendations for preventing and 

PubMed

 

11. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010 Apr;49(4):259–68.

PubMed     CrossRef

.

.

Tel No: +603-7931 7900
Fax No: +603-7932 1400

 

 

D-13A-06, Menara Suezcap 1, KL Gateway,
No.2 Jalan Kerinchi, Gerbang Kerinchi Lestari,
59200 Kuala Lumpur, Malaysia.

www.aseancardiology.org

ASEAN HEART Journal is Supported by Unrestricted Grant From 

Committed to therapeutic advances in cardiovascular research